Formulation development of an albendazole self-emulsifying drug delivery system (SEDDS) with enhanced systemic exposure / Razvoj samoemulzifirajućeg sustava za isporuku albendazola (SEDDS) s pojačanom sistemskom apsorpcijom

doi:10.2478/v10007-012-0031-0

Abstract

The aim of the study was to develop and evaluate a self- -emulsifying drug delivery system (SEDDS) formulation to improve solubility and dissolution and to enhance systemic exposure of a BCS class II anthelmetic drug, albendazole (ABZ). In the present study, solubility of ABZ was determined in various oils, surfactants and co-surfactants to identify the microemulsion components. Pseudoternary phase diagrams were plotted to identify the microemulsification existence area. SEDDS formulation of ABZ was prepared using oil (Labrafac Lipopfile WL1349) and a surfactant/ co-surfactant (Tween 80/PEG 400) mixture and was characterized by appropriate studies, viz., microemulsifying properties, droplet size measurement, in vitro dissolution, etc. Finally, PK of the ABZ SEDDS formulation was performed on rats in parallel with suspension formulation. It was concluded that the SEDDS formulation approach can be used to improve the dissolution and systemic exposure of poorly water-soluble drugs such as ABZ.

References

1. J. R. Robinson, Introduction: semi-solid formulations for oral drug delivery, Bull. Tech. Gattefosse 89 (1996) 11-13.
Search in Google Scholar
2. A. K. Meena, D. V. Ratnam, G. Chandraiah, D. D. Ankola, P. R. Rao and M. N. Kumar, Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure in treating hyperlipidemia, Lipids 43 (2008) 231-241; DOI: 10.1007/s11745-007-3142-5.10.1007/s11745-007-3142-5
Search in Google Scholar
3. D. V. Ratnam, G. Chandraiah, A. K. Meena, P. Ramarao and M. N. Kumar, The co-encapsulated antioxidant nanoparticles of ellagic acid and coenzyme Q10 ameliorate hyperlipidemia in high fat diet fed rats, J. Nanosci. Nanotechnol. 9 (2009) 6741-6746.10.1166/jnn.2009.1461
Search in Google Scholar
4. C. W. Pouton, Effects of the inclusion of a model drug on the performance of self-emulsifying formulations, J. Pharm. Pharmacol. 37 (1985) Suppl. 12:1P; DOI: 10.1111/j.2042-7158.1985.tb14073.
Search in Google Scholar
5. C. W. Pouton, Self-emulsifying drug delivery systems: assessment of the efficiency of emulsification, Int. J. Pharm. 27 (1985) 335-348; DOI: 10.1016/ 0378-5173(85)90081-X.
Search in Google Scholar
6. C. W. Pouton, Formulation of self-emulsifying drug delivery systems, Adv. Drug. Deliv. Rev. 25 (1997) 47-58; DOI: 10.1016/S0169-409X(96)00490-5.10.1016/S0169-409X(96)00490-5
Search in Google Scholar
7. H. Shen and M. Zhong, Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin, J. Pharm. Pharmacol. 58 (2006) 1183-1191; DOI: 10.1211/jpp.58.9.0004.10.1211/jpp.58.9.0004
Search in Google Scholar
8. N. H. Shah, M. T. Carvajal, C. I. Patel, M. H. Infeld and A. W. Malick, Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs, Int. J. Pharm. 106 (1994) 15-23; DOI: 10.1016/0378-5173(94)90271-2.10.1016/0378-5173(94)90271-2
Search in Google Scholar
9. T. R. Kommuru, B. Gurley, M. A. Khan and I. K. Reddy, Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment, Int. J. Pharm. 212 (2001) 233-246; DOI: 10.1016/ S0378-5173(00)00614-1.
Search in Google Scholar
10. A. A. Kale and V. B. Patravale, Design and evaluation of self-emulsifying drug delivery systems (SEDDS) of nimodipine, AAPS Pharm. Sci. Tech. 9 (2008) 191-196; DOI: 10.1208/s12249-008-9037-9.10.1208/s12249-008-9037-9
Search in Google Scholar
11. J. I. Tang, J. Sun and Z. G. He, Self-emulsifying drug delivery systems: strategy for improving oral delivery of poorly soluble drugs, Curr. Drug Therapy 2 (2007) 85-93.
Search in Google Scholar
12. P. Gao, B. D. Rush, W. P. Pfund, T. Huang, J. M. Bauer W. Morozowich, M. S. Kuo and M. J. Hageman, Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability, J. Pharm. Sci. 87 (2003) 2386-2398; DOI: 10.1002/jps.10511.10.1002/jps.10511
Search in Google Scholar
13. G. C. Cook, Use of benzimidazole chemotherapy in human helminthiases: Indications and efficacy, Parasitol. Today 6 (1990) 133-136; DOI: 10.1016/0169-4758(90)90232-S.10.1016/0169-4758(90)90232-S
Search in Google Scholar
14. E. Galia, J. Horton and J. B. Dressman, Albendazole generics: a comparative in vitro study, Pharm. Res. 16 (1999) 1871-1875; DOI: 10.1023/A:1018907527253.10.1023/A:1018907527253
Search in Google Scholar
15. I. M. Rigter, H. G. Schipper, R. P. Koopmans, H. J. M. Van Kan, H. W. Frijlink, P. A. Kager and H. J. Guchelaar, Relative bioavailability of three newly developed albendazole formulations: a randomized crossover study with healthy volunteers, Antimicrob. Agents Chemother. 48 (2004) 1051-1054; DOI: 10.1128/ AAC. 48.3. 1051-1054.2004.
Search in Google Scholar
16. C. T. Dollery, Albendazole, in Therapeutic Drugs, 2nd ed., Churchill Livingstone, Edinburgh 1999, pp. 184-188.
Search in Google Scholar
17. J. J. García, F. Bolas and J. J. Torrado, Bioavailability and efficacy characteristics of two different oral liquid formulations of albendazole, Int. J. Pharm. 250 (2003) 351-358; DOI: 10.1016/S0378-5173(02)00559-8.10.1016/S0378-5173(02)00559-8
Search in Google Scholar
18. S. Torrado, S. Torrado, R. Cadorniga and J. J. Torrado, Formulation parameters of albendazole solution, Int. J. Pharm. 140 (1996) 45-50; DOI: 10.1016/0378-5173(96)04545-0.10.1016/0378-5173(96)04545-0
Search in Google Scholar
19. S. Torrado, M. L. López, G. Torrado, F. Bolás, S. Torrado and R. Cadórniga, A novel formulation of albendazole solution: oral bioavailability and efficacy evaluation, Int. J. Pharm. 156 (1997) 181-187; DOI: 10.1016/S0378-5173(97)00204-4.10.1016/S0378-5173(97)00204-4
Search in Google Scholar
20. P. A. Redondo, A. I. Alvarez, J. L. García, C. Villaverde and J. G. Prieto, Influence of surfactants on oral bioavailability of albendazole based on the formation of the sulphoxide metabolites in rats, Biopharm. Drug Dispos. 19 (1998) 65-70.10.1002/(SICI)1099-081X(199801)19:1<65::AID-BDD76>3.0.CO;2-8
Search in Google Scholar
21. H. Wen, R. R. New, M. Muhmut, J. H. Wang, Y. H. Wang, J. H. Zhang, Y. M. Shao and P. S. Craig, Pharmacology and efficacy of liposome entrapped albendazole in experimental secondary alveolar echinococcosis and effect of co-administration with cimetidine, Parasitology 113 (1996) 111-121; DOI: 10.1017/S003118200006635X.10.1017/S003118200006635X
Search in Google Scholar
22. S. Torrado, S. Torrado, J. J. Torrado and R. Cadórniga, Preparation, dissolution and characterization of albendazole solid dispersion, Int. J. Pharm. 140 (1996) 247-250; DOI: 10.1016/0378-5173(96)04586-3.10.1016/0378-5173(96)04586-3
Search in Google Scholar
23. M. L. Lopez, S. Torrado, S. Torrado, A. R. Martínez and F. Bolás, Improvement of albendazole efficacy against enteral, but not against parenteral stages of Trichinella spiralis by preparing solid dispersions in polyvinylpyrrolidone, Chemotherapy 43 (1997) 430-435; DOI: 10.1159/000239602.10.1159/000239602
Search in Google Scholar
24. R. Kalaiselvan, G. P. Mohanta, K. Kannan, P. K. Manna and R. Manavalan, Optimization of drug-polymer mixing ratio in albendazole-polyvinylpyrrolidone solid dispersion by moisture absorption studies, Acta. Pharm. Sci. 48 (2006) 141-151.
Search in Google Scholar
25. J. A. Castillo, J. Palomo-Canales, J. J. Garcia, J. L. Lastres, F. Bolas and J. J. Torrado, Preparation and characterization of albendazole β-cyclodextrin complexes, Drug. Dev. Ind. Pharm. 25 (1999) 1241-1248; DOI: 10.1081/DDC-100102294.10.1081/DDC-100102294
Search in Google Scholar
26. G. Piel, B. Evrard, T. Van Hees, G. Llabres and L. Delattre, Development of a parenteral and of an oral formulation of albendazole with cyclodextrins, STP. Pharma. Sci. 9 (1999) 257-260.
Search in Google Scholar
27. T. Mukherjee and F. M. Plakogiannis, Development and oral bioavailability assessment of a supersaturated self-microemulsifying drug delivery system (SMEDDS) of albendazole, J. Pharm. Pharmacol. 62 (2010) 1112-1120; DOI: 10.1111/j.2042-7158.2010.01149.x.10.1111/j.2042-7158.2010.01149.x
Search in Google Scholar
28. C. W. Pouton, Lipid formulations for oral administration of drugs: non- emulsifying, self-emulsifying and self-microemulsifying drug delivery systems, Eur. J. Pharm. Sci. 11 (2000) S93-S98; DOI: 10.1016/S0928-0987(00)00167-6.10.1016/S0928-0987(00)00167-6
Search in Google Scholar
29. V. Borhade, H. Nair and D. Hegde, Design and evaluation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus, AAPS Pharm. Sci. Tech. 9 (2008) 13-21; DOI: 10.1208/s12249-007-9014-8.10.1208/s12249-007-9014-8
Search in Google Scholar
30. K. Sharma, M. Kandaswamy, C. Mithra, A. K. Meena, S. Giri, S. Rajagopal and R. Mullangi, Highly sensitive LC-MS/MS-ESI method for simultaenous quantitation of albendazole and ricobendazole in rat plasma and its application to a rat pharmacokinetic study, Biomed. Chromatogr. 26 (2011) 247-255; DOI: 10.1002/bmc.1654.10.1002/bmc.165421633966
Search in Google Scholar
31. H. Jung, M. Hurtado, M. Sanchez, M. T. Medina and J. Sotelo, Clinical pharmacokinetics of albendazole in patients with brain cysticercosis, J. Clin. Pharmacol. 32 (1992) 28-31.10.1002/j.1552-4604.1992.tb03783.x1740534
Search in Google Scholar
32. J. Sotelo and H. Jung, Pharmacokinetic optimization of treatment of neurocysticercosis, Clin. Pharmacokinet. 34 (1998) 503-515.10.2165/00003088-199834060-000069646011
Search in Google Scholar

Formulation development of an albendazole self-emulsifying drug delivery system (SEDDS) with enhanced systemic exposure / Razvoj samoemulzifirajućeg sustava za isporuku albendazola (SEDDS) s pojačanom sistemskom apsorpcijom

Abstract

Paradigm

My account